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Abstract
Background Intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-guided therapy is central to neurocritical care for
traumatic brain injury (TBI) patients. We sought to identify time-dependent critical thresholds for mortality and unfavourable
outcome for ICP and CPP in non-craniectomised TBI patients.
Methods This is a retrospective cohort study of 355 patients with moderate-to-severe TBI who received ICP monitoring and
were managed without decompressive craniectomy in a tertiary hospital neurocritical care unit. Patients were grouped in 2 × 2
tables according to survival/death or favourable/unfavourable outcomes at 6 months and serial thresholds of mean ICP and CPP,
using increments of 0.1 and 0.5 mmHg respectively. Sequential chi-square analysis was performed, and the thresholds yielding
the highest chi-square test statistic were taken as having the best discriminative value for outcome. This process was repeated
over monitoring periods of 1, 3, 5 and 7 days and for each day of recording to establish time-dependent thresholds. The same
analysis was performed for age and sex subgroups.
Results Global ICP thresholds were 21.3 and 20.5 mmHg for mortality and unfavourable outcome respectively (p < 0.001). After
the first day of ICP monitoring, ICP thresholds fell to between 15 and 20 mmHg and remained significant (p < 0.05). Significant
time-dependent CPP thresholds for mortality or unfavourable outcome were often not identified, and no identifiable trends were
produced.
Conclusion Critical ICP thresholds in non-craniectomised TBI patients vary with time and fall below established ICP targets after
the first day of monitoring.
Keywords Neuromonitoring . Neurocritical care . Traumatic brain injury . Threshold . Intracranial pressure . Cerebral perfusion
pressure
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Introduction
Intracranial pressure (ICP) monitoring is a fundamental
strategy in neurocritical care for traumatic brain injury
(TBI) and is used routinely to guide medical and surgi-
cal intervention. Though well-supported by retrospective
[1, 11, 12] and prospective studies [24], there is no
level I evidence for outcome benefit from treatment
guided by ICP monitoring. The only randomised con-
trolled trial showed no improvement in outcome associ-
ated with maintaining monitored ICP below 20 mmHg
compared to treatment guided by clinical and radiolog-
ical assessment. Among many worthwhile caveats, the
authors note that the lack of demonstrable efficacy may
be attributed in part to the use of a generic, universal
target ICP [9] and poor monitoring method (instant end-
hour values).
Intracranial hypertension is commonly defined at a
threshold of 20–25 mmHg in clinical practice, and
unfavourable outcomes have been described at ICP
thresholds ranging from 15 to 25 mmHg [5, 10, 16, 20].
Recent consensus guidelines from the Brain Trauma
Foundation (BTF) specify a critical ICP threshold of
22 mmHg below which ICP should be maintained [8],
based on evidence that ICP above this value best predicts
mortality and severe morbidity [22].
However, it has been suggested that optimal ICP
thresholds may vary with demographic characteristics
such as age and sex [22]. It also stands to reason that
patients treated medically may have different ICP thresh-
olds than those treated with decompressive craniectomy
(DC), as these groups experience distinct intracranial bio-
mechanical parameters. Other physiological variables, for
example, state of autoregulation, probably play additional
roles [14]. Thus, applying a universal threshold to ICP
management fails to account for the heterogeneity in
patient-specific injury patterns and response to treatment
interventions. Of particular importance, the 22-mHg
threshold is derived from a mixed cohort of patients man-
aged with and without DC. Surprisingly low time-
dependent ICP thresholds for outcome have recently been
described in DC patients [19], but time-dependent ICP
threshold analysis has not been conducted in an exclusive
cohort of patients managed without DC (non-DC).
Similarly, BTF guidelines recommend targeting cere-
bral perfusion pressure (CPP) between 60 and
70 mmHg based on available evidence [2, 8, 22], but
note the growing consensus that individualised cerebral
perfusion pressure thresholds aimed at achieving optimal
cerebrovascular reactivity may be associated with supe-
rior outcomes [3, 23]. The same may be true of ‘critical
threshold’ of ICP [14]—although this point is much
worse documented.
Thus, there is a need to identify more precise ICP and
CPP thresholds that account for individual variation in
age, sex, disease natural history and treatment interven-
tion. The primary aim of this study is to evaluate, in a
non-DC TBI patient population, ICP and CPP thresholds
associated with 6-month morbidity and mortality.
Further, we wish to evaluate whether these thresholds
vary based on the recording period utilised, or based on
the day of recording. Finally, secondary aims were to
preliminarily assess if these critical thresholds vary based
on age and sex.
Methods
Patient population
This is an observational cohort study with retrospective
analysis of 355 patients within a TBI database. A portion
of this population has been described in the previous ICP
threshold work done by Sorrentino et al. [22]. These pa-
tients were those with a minimum of 6 h of archived high-
frequency physiologic recordings. All patients were ad-
mitted to the Neurosciences and Trauma Critical Care
Unit (NCCU) at Cambridge University Hospitals NHS
Foundation Trust (CUH) between March 2005 and
December 2016. Patients suffered either moderate-to-
severe TBI or mild TBI and subsequently deteriorated to
a point where they required ICP monitoring and sedation
and mechanical ventilation as part of ICP management.
As such, the timing of ICP monitoring, both in duration
and time to initiation after injury, was variable. Treatment
received included standard ICP-directed therapy, with an
ICP goal of less than 20 mmHg and CPP goal of greater
than 60 mmHg.
Age, sex, Glasgow Coma Scale (GCS) at admission, injury
severity score (ISS) and Glasgow Outcome Scale (GOS) at
6 months were prospectively collected and recorded in the
database. Two binary outcome classifications were recorded
for each patient at 6 months, namely, alive vs dead and
favourable vs unfavourable outcome. Unfavourable outcome
was defined as GOS < 4.
All data were fully anonymised, and no attempt was made
to re-access clinical records for additional information. As
such, formal patient or proxy consent was not required.
Within our institution, patient data may be collected with a
waiver of formal consent, as long as it remains fully
anonymised, with no method of tracing this back to an indi-
vidual patient. Patient physiologic, demographic and outcome
data were collected by the clinicians involvedwith patient care
and subsequently recorded in an anonymous format. This
anonymous data is then provided for future research purposes.
Such data curation remains within compliance for research
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integrity as outlined in the Governance Arrangements for
Research Ethics Committees (GAfREC), September 2011
guidelines, section 6.0 [17, 25].
The exact number of overlapping patients between the cur-
rent work and Sorrentino et al. is unknown. As our local pro-
spective signal database is a fluid entity, with patient data
added at various points during their hospital stay, we are un-
able to determine which patients exactly overlap between
these two works. In addition, we do not have access to the
original anonymous patient identifier codes from the
Sorrentino work, further impeding our ability to give exact
numbers of overlap.
Signal acquisition and processing
Intracranial pressure was acquired via an intraparenchymal
strain gauge probe (Codman ICP MicroSensor; Codman &
Shurtleff Inc., Raynham, MA). Arterial blood pressure was
obtained through either radial or femoral lines connected to
pressu re t r ansduce r s (Bax te r Hea l thca re Corp .
CardioVascular Group, Irvine, CA). All signals from the
above devices were sampled at minimum 50 Hz and re-
corded using digital data transfer or digitised via an A/D
converter (DT9801 or DT9803; Data Translation,
Marlboro, MA), where appropriate, using the ICM+ soft-
ware (Cambridge Enterprise Ltd., Cambridge, UK, http://
icmplus.neurosurg.cam.ac.uk). Signal artefacts were
removed manually prior to further processing or analysis.
CPP was determined as the difference between mean
arterial pressure and ICP.
Minute-by-minute data processed originally by ICM+
were exported into comma separated values format
(CSV). Using R statistical software (R Core Team
(2016). R: A language and environment for statistical
computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/),
various data sheets were created including grand mean
over entire recording period, first 24 h, first 72 h, first
120 h and first 168 h. Furthermore, data was also
averaged for each day of recording in order to assess
time dependence of the critical thresholds.
Statistics
All statistics were completed using R statistical software.
Descriptive statistics were applied to summarise demo-
graphic data. Normality was tested using the Shapiro-
Wilk test for demographic variables and measured indi-
ces, all of which were determined to be non-parametric.
Non-parametric tests of independence were used to com-
pare demographic and clinical characteristics in patients
of each binary outcome classification. Critical thresholds
for outcome were derived using sequential chi-square
analysis. This method has been previously applied in oth-
er publications assessing thresholds for ICP, CPP and con-
tinuous autoregulation indices in TBI [21, 22, 27], and its
use allowed direct comparison of time-, duration- and
treatment-dependent results with existing thresholds.
Sequential 2 × 2 binary outcome contingency tables were
constructed, grouping patients by (1) survival or
dichotomised outcome (GOS ≥ 4 vs GOS < 4) and (2) av-
erage ICP and CPP greater or less than sequential thresh-
olds in 0.1 and 0.5 mmHg increments respectively. The
ICP or CPP threshold returning the highest chi-square test
statistic value was assumed to have the best discriminative
value.
The same analysis was repeated for each subgroup of
sex (male vs female) and age (≤ 55 vs < 55). Age catego-
ries were set to mirror those used in the initial landmark
threshold analysis [22]. Whole cohort and subgroup anal-
ysis was repeated for ICP and CPP values averaged over
the first 24 h and 3, 5, 7 and 10 days of ICP monitoring to
create duration-of-monitoring-dependent thresholds.
Subsequently, the same analysis was repeated again for
ICP and CPP means in 24 h slices to determine critical
thresholds for each day of the first 7 days of ICP moni-
toring. Statistical significance was set at p < 0.05 for all
results. p values were corrected for multiple testing using
the Benjamini and Hochberg FDR method, and the results
that remain statistically significant were highlighted.
Graphical production was completed using the ggplot2
package in R.
Finally, univariable logistic regression analysis was
performed for the statistically significant ICP thresholds,
assessing the area under the receiver operating curve
(AUC) and 95% confidence intervals (CI) associated
with both dichotomised outcomes. This was conducted
across all time periods analysed. This was not conduct-
ed for CPP, given poor threshold discrimination on chi-
square testing.
Results
Cohort characteristics
A total of 355 patients (271 male, 84 female) were
included in the study, with a mean age of 40.6 (SD
17.2) and a median admission GCS of 7 (IQR 3–9).
The mean duration of ICP monitoring was 6.81 days
(SD 5.99). Six months after admission, 172 patients
had favourable outcomes as assessed by the Glasgow
Outcome Score (low or moderate disability), and 183
had unfavourable outcomes (severe disability, persistent
vegetative state or death) of whom 63 had died. Mean
age and mean ICP were significantly higher among
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patients who died or had an unfavourable outcome.
Mean ICP monitoring period was also higher in patients
with unfavourable outcome. Median admission GCS was
lower in patients who died or unfavourable outcome,
while sex distribution, median ISS and mean CPP were
not significantly different (Table 1). Mean ICP and CPP
by patient outcome (alive/dead and favourable/
unfavourable) for each day and duration of monitoring
are given in Appendix A.
Overall thresholds
In the whole cohort across the full duration of ICPmonitoring,
the overall ICP threshold for mortality was 21.3 mmHg (χ2 =
42.90, p < 0.001). The threshold for the unfavourable outcome
was 20.5 mmHg (χ2 = 20.73, p < 0.001) (Fig. 1).
The ICP thresholds for mortality in patients aged > 55 (n =
78) and ≤ 55 (n = 277) were 14.7 mmHg (χ2 = 8.3; p =
0.0039) and 20.7 mmHg (χ2 = 39.34; p < 0.001) respectively,
while the thresholds for unfavourable outcome were
19.9 mmHg (χ2 = 4.97; p = 0.026) and 20.6 mmHg (χ2 =
17.35; p < 0.001) respectively. Male and female patients were
also evaluated, but given the small number of female relative
to male patients, the strength of conclusions is limited. Sex-
specific results are presented in Appendix B. Univariable lo-
gistic regression analysis for the statistically significant thresh-
olds can be found in Appendix C, providing AUC and 95%CI
for the dichotomised outcomes across all statistically signifi-
cant ICP thresholds identified.
Duration-dependent thresholds
Sequential chi-square analysis was repeated across all subgroups
during the first 24 h and 3, 5 and 7 days of ICP monitoring. The
whole cohort results are presented in Fig. 2. Over the first 24 h,
the threshold for mortality was higher than the overall threshold
(24.7 mmHg; χ2 = 31.30; p < 0.001) then dropped below
20 mmHg over longer periods of monitoring. The threshold
for unfavourable outcome remained comparatively stable across
all recorded lengths of monitoring, though significant
unfavourable outcome thresholds could not be identified at 7.
The duration-dependent ICP thresholds for males and pa-
tients of age ≤ 55 closely followed the pattern of the overall
cohort. The 24-h threshold for the unfavourable outcome was
lower in female patients. Female mortality thresholds mirrored
overall thresholds over 24 h and 3 days, but significant thresh-
olds could not be identified beyond this (Appendix B). In older
patients, lower thresholds were identified for both mortality and
unfavourable outcome in the first 24 h, but further duration-
dependent thresholds are not significant (Appendix D). It must
be acknowledged that the number of patients included dropped
over longer durations of recording.
Time-dependent thresholds
Sequential chi-square analysis was repeated for each 24-h pe-
riod for the first 7 days of ICPmonitoring. In the whole cohort,
ICP threshold for mortality dropped from 24.7 mmHg (χ2 =
31.30; p < 0.001) in the first day to 16.5 mmHg (χ2 = 29.29;
p < 0.001) in the second day and remained below 20 mmHg
for each 24 h period assessed. The threshold for unfavourable
outcome dropped from 20.3mmHg (χ2 = 36.41; p < 0.001) on
the first day to remain at or below 20 mmHg for each day
where a significant threshold was identified (Fig. 3).
Time-dependent thresholds in the male and young sub-
groups were similar to overall cohort. Where significant
thresholds were identified for the female subgroup, they were
also similar with the exception of a lower day 1 outcome
Table 1 Cohort characteristics
Whole cohort Favourable
outcome
(GOS ≥ 4)
Unfavourable
outcome
(GOS < 4)
p value Survived Died p value
Number of patients 355 172 183 292 63
Sex 0.76 0.27
Male
Female
271
84
133
39
138
45
219
73
52
11
Mean age (SD) 40.6 (17.2) 38.2 (17.0) 43.0 (17.0) 0.0091 39.4 (16.6) 46.6 (18.5) 0.0026
Mean ICP (mmHg) (SD) 14.1 (7.7) 12.6 (4.6) 15.4 (19.5) 0.0039 12.9 (5.8) 19.4 (12.0) < 0.001
Mean CPP (mmHg) (SD) 77.5 (8.5) 77.6 (6.7) 77.6 (9.9) 0.31 77.9 (7.5) 76.2 (11.9) 0.39
Mean ICPmonitoring period (days) (SD) 6.81 (5.99) 6.39 (5.50) 7.21 (6.38) 0.0030 6.95 (6.21) 6.21 (4.78) 0.31
Median admission GCS (IQR) 7 (3.25–9) 8 (5–11) 6 (3–8) < 0.001 7 (4–10) 4 (3–8) 0.0026
Median ISS 33 (25–41) 31.5 (25–38) 33 (25–41) 0.20 33 29.5 0.76
CPP cerebral perfusion pressure, GCS Glasgow Coma Scale, GOS Glasgow Outcome Score, ICP intracranial pressure, IQR interquartile range, ISS
injury severity score, SD standard deviation
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threshold (Appendix B). Patients aged > 55 had lower ICP
thresholds for both mortality and unfavourable outcome for
the first 2 days of monitoring, but significant thresholds were
not identified for later days (Appendix D).
Discussion
ICP
This study presents the first systematic analysis of time-
dependent ICP thresholds for mortality and unfavourable out-
come in TBI patients managed without DC. The overall
thresholds, based on the entire recording period, that best dis-
criminate mortality and unfavourable outcome were 21.3 and
20.5 mmHg respectively. These thresholds were the most sta-
tistically significant ICP thresholds associated with global pa-
tient outcome, more so than a threshold of 20 (i.e. a commonly
applied treatment threshold in clinical practice). They indicate
that patients with mean ICP values above these particular
thresholds had the strongest association with worse
dichotomised global outcomes at 6 months. These are slightly
below the universal threshold of 22 mmHg recommended in
the current consensus guidelines [8], though they remain in
the 20–25 mmHg range usually applied in clinical practice.
However, time-specific analysis revealed variable ICP thresh-
olds over the first week of monitoring. After the first 24 h of
monitoring, the daily thresholds fell and remained between 15
and 20 mmHg. This was apparent both when the data was
grouped by duration of monitoring and analysed on a day-
by-day basis.
Sex-specific analysis revealed female patients had a higher
overall ICP threshold for mortality, but the duration- and time-
dependent ICP thresholds followed a similar pattern to those
of male patients, with only occasional variations. Given the
low number of female patients in the cohort, it is not possible
to comment definitively on significant sex differences in ICP
threshold based on this data alone. It is interesting to note
lower ICP thresholds for mortality and unfavourable outcome
in older patients, both overall and in the first 2 days of ICP
monitoring. Though carrying a similar caveat due to the low
proportion of older patients, this is in keeping with previous
evidence that older patients may exhibit higher vulnerability
to ICP insult [22], particularly in the early stages of ICP man-
agement. It is also notable that chi-square test statistic values
are generally substantially higher in mortality thresholds for
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Fig. 1 Sequential chi-square analysis for intracranial pressure threshold.
The values returning the highest chi-square test statistic, and therefore
having the highest discriminatory value for outcome, were taken as
thresholds and are denoted by p values. Bold p values remained
significant on correction for multiple comparisons. ICP denotes
intracranial pressure
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both ICP and CPP, suggesting a stronger association between
these metrics and mortality as compared with the
unfavourable outcome. This is concordant with previous
results [22].
Our results establish ICP thresholds for non-DC patients
that are slightly distinct from the threshold previously de-
scribed for a mixed cohort [22]. Moreover, it is unsurprising
to find these thresholds differ to those recently described for
DC patients [19]. These results, taken together, reinforce the
need to develop individualised ICP thresholds, as treatment
modalities and patient characteristics introduce tremendous
heterogeneity.
The ultimate goal is to derive ICP thresholds that derive
rationally from patient-specific pathophysiology. There is ev-
idence that the tolerability of ICP insults vary between patients
depending on autoregulatory capacity [13] and intracranial
pressure-volume dynamics [7]. Lazardis et al. [14] used a
pressure reactivity index (PRx—correlation between ICP
and MAP) cut-off of > 0.2 to define patient-specific ICP
thresholds at which cerebrovascular pressure reactivity was
deranged. These variable thresholds yielded superior outcome
prediction than fixed thresholds of 20 or 25 mmHg. In the
context of our findings, which show a time-dependent ICP
threshold that usually remains below 20 mmHg, pulse ampli-
tude index (PAx—correlation between pulse amplitude of ICP
and MAP) may be superior for the latter strategy, as it is
proven to be a superior outcome predictor than PRx at ICP
< 20 mmHg [4].
CPP
We explored CPP thresholds using the same methodology.
The results showed no identifiable trends, and significant
time-dependent thresholds for mortality or unfavourable out-
come were often not identified, even in the whole cohort and
in well-populated subgroups (males and young patients). As
no significant conclusions could be drawn from these results,
they have not been included in the manuscript.
This lack of ability to determine global clinically signifi-
cant CPP thresholds likely stems from the issue of targeting a
global CPP target for everyone. CPP thresholds in TBI have
remained relatively elusive for some time now, with conflict-
ing literature on appropriate CPP ranges to target, leading to
changes in recommendations between various renditions of
p < 0.001
p < 0.001
p = 0.0022
p < 0.001 p < 0.001
p = 0.0034
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NS15.0
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Fig. 2 Whole cohort thresholds by duration of monitoring ICP. Bold
p values remained significant on correction for multiple comparisons.
Number of patients with available ICP data over each monitoring
period were as follows: 24 h, 340; 3 days, 277; 5 days, 217; and
7 days, 163. ICP denotes intracranial pressure; NS not significant
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the BTF guidelines [6, 8]. Though the lack of significant re-
sults within this study does not provide definitive evidence,
we believe they do provide further support of ‘personalised’
CPP targets in TBI. Such personalised CPP targets include
those suggested by the CPP optimum (CPPopt) concept, with
numerous papers to date suggesting a stronger link between
CPPopt and patient outcome [18]. The definitive link between
these personalised CPP targets in TBI has yet to be deter-
mined, with prospective randomised trials underway
[COGITATE, ClinicalTrials.gov Identifier: NCT02982122].
We do not believe that the lack of results for CPP suggests
that ICP is more important and should be preferentially targeted
in TBI therapy. It is likely the way we currently view CPP is the
issue, arguing for a change in the way we analyse and target it.
Limitations
First, this study is limited by its retrospective design, making it
impossible to control for the influence of treatment targets on
the derived thresholds. Additionally, as high ICP may reflect
the global severity of a patient’s condition, it is impossible to
determine the direct effect of ICP thresholds on the outcome
without prospective validation. Furthermore, as these data
were collected over 11 years, changing management patterns
over time may confound the results. Given the potential for
treatment heterogeneity across our patient population, this
needs further acknowledgement as a limitation. The informa-
tion within our database was retrospectively accessed for the
purpose of this study, without the ability to re-access charts for
missing information. Thus, comments on treatment intensity
(i.e. doses of hypertonic agents, use of sedation, cerebrospinal
fluid drainage, use of barbiturates) and its potential relation to
the thresholds seen cannot be made based on this data. This is
an important limitation of our study, as not only can various
treatments directly impact the ICP and CPP values recorded,
but also those patients with medically refractory ICP may
have had a reduction on therapy secondary to futility. Such a
reduction in therapy could lead to persistent ICP elevations
skewing the thresholds found within our study. However, with
that said, we believe that the number of patients that would fall
into this category would be quite small within the population
studied, as those with persistent refractory ICP issues typically
undergo a secondary DC at our institution. All DC patients
were excluded from this study to avoid such confounding.
p < 0.001
p < 0.001 p < 0.001
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p < 0.001
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Fig. 3 Whole cohort ICP thresholds by day of monitoring. Not
significant ICP outcome point at 6 days removed. Bold p values
remained significant on correction for multiple comparisons. Number of
patients with available ICP data for each day of monitoring were as
follows: day 1,340; day 2,296; day 3,270; day 4,234; day 5,199;
day 6,176; and day 7,144. ICP denotes intracranial pressure; NS not
significant
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Thus, despite the absence of information on treatment inten-
sity, we are confident that the results presented are not signif-
icantly skewed due to outliers.
Furthermore, despite the exclusion of DC patients from our
study, there were subjects in our study population that had
medically refractory ICP (i.e. levels persistently above
20 mmHg during a large portion of their ICP stay). It is un-
known why these patients did not undergo DC, as this was not
recordedwithin our database that was retrospectively accessed
for the purpose of this study. It is possible that these patients
represent those that were ‘too sick’ for surgical salvage thera-
py. This further adds to the heterogeneity of our TBI popula-
tion for this study, thus re-emphasising that the results found
for ICP and CPP thresholds are preliminary, with further val-
idation in a multicentre cohort required.
Second, although 355 patients were included in the study,
the characteristic demographic pattern of TBI meant that the
statistical power of less well-populated subgroup analysis was
weakened by small sample size, notably in females and patients
aged > 55. This may explain the relative absence of statistically
significant thresholds in these subgroups especially. Thus, we
were unable to definitively comment on whether there is a
significant difference in ICP thresholds between age and sex
groups. There exists the potential that age-related cerebral atro-
phy can confound the ICP thresholds seen. With advanced age,
cerebral atrophy increases. Thus, to reach the same ICP values
as younger patients, one could argue that more severe intracra-
nial injury is required in these elderly patients, with larger mass
lesions/oedema volume required. Thus, when assessing ICP
thresholds associated with outcome, this potential injury sever-
ity discrepancy between the young and elderly, with similar ICP
values, may impact the results. Based on the data available in
our database, we were unable to assess this. We are planning a
follow-up study with the ICU cohort from CENTER-TBI [15],
using upwards of 2000 patients, with detailed imaging assess-
ments, to probe into age-specific ICP thresholds and the impact
of intracranial injury patterns.
Third, the time-dependent analysis is limited by values of
ICP averaged over 24 h. Therefore, it was not possible in this
work to identify time-dependent critical thresholds over a
shorter timescale. Moreover, the average ICP values do not
directly relate to time spent above putative thresholds, or ICP
‘dose’ [13, 26]. The drop in ICP-based critical thresholds after
the first 24 h of recordingmay be secondary to either treatment
effect, or reflect the ‘dose’ response to ICP, where absolute
thresholds may be less useful than the amount of time spent
above such values [13, 26]. While this generally did not have
an effect on the derived ICP thresholds, the accuracy of the
sequential chi-square method of threshold analysis is limited
at extreme ICP values by small cell sizes.
Fourth, a further limitation of this retrospective database
study is lack of clarity on cause of mortality. The information
available within our dataset includes only a rough global
assessment of patient outcome at 6-months (i.e. GOS), with-
out elaboration on cause of mortality. Thus, we are unable to
separate those who died secondary to neurological causes
from other in-hospital causes within this study. This would
have provided potentially interesting insight into differences
in ICP and CPP thresholds based on mortality causes. Given
this limitation within our study, this will be assessed in the
upcoming analysis of the multicentre high-resolution ICU co-
hort in the CENTER-TBI [15], with the hope that further light
may be shed on this topic.
Fifth, DC patients were specifically excluded to avoid the
potential for confounding effects on the ICP thresholding.
Much additional work is required in this population to
assessed ICP and CPP critical thresholds associated with glob-
al outcome. In the presence of DC, the value returned from
ICP monitoring is exceedingly difficult to interpret, given an
open cranial vault and influence from atmospheric pressure on
the readings. Thus, despite the difference in ICP threshold
discovered between our work and the original Sorrentino
study, we refrain from making generalised comments on ICP
thresholds from DC patient populations at this time, until fur-
ther objective analysis of this population is conducted. This
work is currently under way.
Finally, it is important to emphasise that this work is pre-
liminary. Thus, although we have identified differing trends
within the non-DC population, and a change in threshold over
time, further confirmatory work is required prior to any change
in guideline-based threshold targets. We must re-emphasise
that the results of this analysis should not change current ICP
treatment thresholds recommended in current guidelines. In
addition, having separate thresholds for mortality and
favourable/unfavourable outcome is not entirely clinically use-
ful, as it pertains to threshold targeting for ICP-directed thera-
pies. These different thresholds only provide information re-
garding potentially predicting functional outcome. We plan to
undertake further prospective analysis using the ICU cohort
data-set from CENTER-TBI, to better define ICP thresholds
over time and perform more detailed subgroup analysis.
Conclusion
A global ICP threshold for non-DC TBI patients is identified
as 21.3 mmHg for mortality and 20.5 mmHg for unfavourable
outcome, similar to what has been described in the BTF guide-
lines. However, after the first day of ICP monitoring, time-
dependent ICP thresholds fell to between 15 and 20 mmHg,
lower than the targets recommended in current guidelines and
used in clinical practice. These thresholds are lower still in
older patients. These results underscore the importance of de-
veloping individualised ICP thresholds based on demo-
graphics, treatment modalities, patient-specific pathophysiol-
ogy and, possibly, other physiological markers.
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